WILMINGTON, Mass., March 1 /PRNewswire-FirstCall/ -- CardioTech International, Inc. , a developer and manufacturer of advanced medical device products treating cardiovascular disease, today announced the appointment of Andrew M. Reed, Ph.D., as Vice President of Technology in charge of CardioPass coronary artery bypass development and biomaterials. Dr. Reed is a world expert in the area of biocompatible and biodurable polyurethanes. He was instrumental in the development of synthetic polyurethane vascular grafts using the patented fabrication technique of phase inversion. He is also the inventor of Mitraflex(R) microporous polyurethane membrane based wound healing products.
Dr. Reed was formerly Executive Vice President, Operations, Specialty Products Division of CCS Medical, Inc. a Florida-based mail order supplier of diabetic testing, wound care, urology and respiratory supplies to Medicare, Medicaid and commercially insured patients. From 1997, Dr. Reed was Executive Vice President, Operations of MPTotalcare, Inc. and Gericare Providers, Inc. companies engaged in providing wound care supplies to home bound seniors. Prior to joining Gericare he was President of PolyMedica Wound Care Company, a division of PolyMedica Corporation, until the division's acquisition by Innovative Technologies PLC.
"I have worked with Dr. Reed for nearly 15 years in the areas of vascular grafts, biodurable polyurethanes and advanced wound dressings," commented Michael Szycher, Ph.D., Chairman and CEO of CardioTech. "Our CardioPass synthetic coronary artery bypass graft is based on the phase-inversion principle. His expertise should prove invaluable in advancing the CardioPass technology."
Dr. Reed held management and research positions with Matrix Membranes, Inc., Mitral Medical, Inc., and Millipore Corporation. His research publications include numerous scientific articles and a portfolio of domestic and international patents relating to the medical and industrial uses of polyurethanes. He also has broad experience in obtaining regulatory approvals for medical devices both in domestic and international markets. Dr. Reed obtained a Bachelor of Science degree in Chemistry and a Doctorate on Polymer Chemistry from the University of Liverpool, U.K. He is a member of the American Chemical Society.
About CardioTech
CardioTech International, Inc. is a medical device company that develops, manufactures and sells advanced products to surgically treat cardiovascular disease. The company is currently developing new products that address annual worldwide markets exceeding $1 billion. It is conducting human clinical trials with CardioPass, its proprietary, synthetic coronary artery bypass graft, and has partnered to develop a drug-eluting stent. The company's corporate headquarters are located in Wilmington, Massachusetts, with operations in California and Minnesota. The company generates revenues from sales of advanced medical devices and disposables used during cardiopulmonary bypass procedures, as well as from contract manufacturing. More information can be found about CardioTech at its website: http://www.cardiotech-inc.com
CardioTech believes that this release contains forward-looking statements that are subject to risks and uncertainties. Such statements are based on management's current expectations and are subject to facts that could cause results to differ materially from the forward-looking statements. For further information you are encouraged to review CardioTech's filings with the Securities and Exchange Commission.
For more information, please contact: CardioTech International, Inc. Michael Szycher, Ph.D. CEO and Chairman 978 657-0075 Catalyst Financial Resources, LLC Tom O'Brien 716 837-3032
CardioTech International, Inc.CONTACT: Michael Szycher, Ph.D., CEO and Chairman of CardioTechInternational, Inc., +1-978-657-0075; or Tom O'Brien of Catalyst FinancialResources, LLC, +1-716-837-3032
Web site: http://www.cardiotech-inc.com//
